Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AspenBio submits IDE for appendicitis blood test:

This article was originally published in Clinica

Executive Summary

AspenBio Pharma has started the ball rolling in seeking approval for its appendicitis blood test, submitting a pre-investigational device exemption to the US FDA. The AppyScore triage test was found to reduce unnecessary surgery by 58% in recent pre-FDA trials of 471 patients. The test also showed a sensitivity of 98% - more accurate than CT scans which are currently considered the best diagnostic method for the condition. Furthermore, CT can be time consuming, expensive, and exposes patients to radiation, claimed the Castle Rock, Colorado firm. AspenBio sees a potentially large market for the test, claiming that some 6 million US patients each year enter hospital emergency rooms complaining of abdominal pain which could be appendicitis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel